<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">539</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2021-20-3-26-30</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Prognostic evaluation of immune thrombocytopenia outcomes in Egyptian children: a retrospective single-center experience</article-title><trans-title-group xml:lang="ru"><trans-title>Prognostic evaluation of immune thrombocytopenia outcomes in Egyptian children: a retrospective single-center experience</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Diab</surname><given-names>Aliaa Mohammed</given-names></name><address><country country="EG">Egypt</country></address><bio xml:lang="en"><p><bold>Aliaa Mohammed Diab</bold>, Pediatric Department, Faculty of Medicine </p><p>Benha</p></bio><bio xml:lang="ru"><p><bold>Aliaa Mohammed Diab</bold>, Pediatric Department, Faculty of Medicine </p><p>Benha </p></bio><email>aliaadiab@yahoo.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Abouamer</surname><given-names>AlRawhaa Ahmed</given-names></name><address><country country="EG">Egypt</country></address><bio><p>Benha</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Motaleb</surname><given-names>Ghada Saad Abdel</given-names></name><address><country country="EG">Egypt</country></address><bio><p>Benha</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Eid</surname><given-names>Khaled Abdelaziem</given-names></name><address><country country="EG">Egypt</country></address><bio><p>Cairo</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Abdelnaiem</surname><given-names>Heba Ismaiel</given-names></name><address><country country="EG">Egypt</country></address><bio><p>Benha</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><institution>Benha University</institution></aff><aff id="aff2"><institution>Cairo University</institution></aff><pub-date date-type="pub" iso-8601-date="2021-10-08" publication-format="electronic"><day>08</day><month>10</month><year>2021</year></pub-date><volume>20</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>26</fpage><lpage>30</lpage><history><date date-type="received" iso-8601-date="2021-10-07"><day>07</day><month>10</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-10-07"><day>07</day><month>10</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/539">https://hemoncim.com/jour/article/view/539</self-uri><abstract xml:lang="en"><p>Immune thrombocytopenia (ITP) is the most common cause of thrombocytopenia in children. This retrospective study was designed to analyze presenting features of ITP cases in Benha, evaluate outcomes in children and determine prognostic factors. This research was accepted by Research Ethics Committee (REC) of Faculty of Medicine, Benha University (chairman: Prof. Nermeen Adly Mahmoud). Ethics comittee refrence number MS 40-3/2019. Records of 308 children with ITP in Benha University Hospitals and Benha Children Hospital haematology clinics between May 2014 and January 2021 were retrospectively analyzed. Socio-demographic, clinical, and laboratory data of the studied children such as age, gender, the type of residence, the date of diagnosis, complaints at presentation, preceding vaccination or infection, the type of bleeding, initial platelet count, LDH (lactate dehydrogenase) level, initial treatment, and outcomes were recorded. A total of 308 children diagnosed with ITP were included, clinical courses were determined as newly diagnosed and chronic in 71.4% and 28.6%, respectively. The median age of patients at diagnosis was 5 ± 3.4 years. The male/female ratio was 1.14. The median age at diagnosis was significantly higher in chronic ITP patients (p &lt; 0.001); patients ≥ 10 years were more likely to develop chronic ITP than younger ones (p = 0.029). Regarding residency, seasonality, type of bleeding and history of preceding infection or vaccination, the difference was not statistically significant. Initial platelet counts &gt; 20 × 10<sup>9</sup> were significantly more prevalent in chronic ITP (p &lt; 0.001). LDH level at presentation was significantly higher in chronic cases (p = 0.046). Initial lines of treatment were the following: steroids, IVIG, and IVIG with steroids (in 88%, 5.2%, and 2.9% of the cases, respectively). A total of 3.9% of the children did not receive any treatment. There was no significant difference in the outcomes between the initial lines of treatment (p = 0.105). In our study, age &gt; 10 years, female gender, higher platelet count and high LDH level at presentation were found to increase the probability of chronic ITP.</p></abstract><trans-abstract xml:lang="ru"><p>Immune thrombocytopenia (ITP) is the most common cause of thrombocytopenia in children. This retrospective study was designed to analyze presenting features of ITP cases in Benha, evaluate outcomes in children and determine prognostic factors. This research was accepted by Research Ethics Committee (REC) of Faculty of Medicine, Benha University (chairman: Prof. Nermeen Adly Mahmoud). Ethics comittee refrence number MS 40-3/2019. Records of 308 children with ITP in Benha University Hospitals and Benha Children Hospital haematology clinics between May 2014 and January 2021 were retrospectively analyzed. Socio-demographic, clinical, and laboratory data of the studied children such as age, gender, the type of residence, the date of diagnosis, complaints at presentation, preceding vaccination or infection, the type of bleeding, initial platelet count, LDH (lactate dehydrogenase) level, initial treatment, and outcomes were recorded. A total of 308 children diagnosed with ITP were included, clinical courses were determined as newly diagnosed and chronic in 71.4% and 28.6%, respectively. The median age of patients at diagnosis was 5 ± 3.4 years. The male/female ratio was 1.14. The median age at diagnosis was significantly higher in chronic ITP patients (p &lt; 0.001); patients ≥ 10 years were more likely to develop chronic ITP than younger ones (p = 0.029). Regarding residency, seasonality, type of bleeding and history of preceding infection or vaccination, the difference was not statistically significant. Initial platelet counts &gt; 20 × 10<sup>9</sup> were significantly more prevalent in chronic ITP (p &lt; 0.001). LDH level at presentation was significantly higher in chronic cases (p = 0.046). Initial lines of treatment were the following: steroids, IVIG, and IVIG with steroids (in 88%, 5.2%, and 2.9% of the cases, respectively). A total of 3.9% of the children did not receive any treatment. There was no significant difference in the outcomes between the initial lines of treatment (p = 0.105). In our study, age &gt; 10 years, female gender, higher platelet count and high LDH level at presentation were found to increase the probability of chronic ITP.</p></trans-abstract><kwd-group xml:lang="en"><kwd>primary immune thrombocytopenia</kwd><kwd>immune thrombocytopenia outcome</kwd><kwd>immune thrombocytopenia prognostic factors</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>primary immune thrombocytopenia</kwd><kwd>immune thrombocytopenia outcome</kwd><kwd>immune thrombocytopenia prognostic factors</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Abadi U., Yarchovsky-Dolberg O., Ellis M.H. Immune thrombocytopenia: recent progress in pathophysiology and treatment. Clin Appl Thromb Hemost 2015;21 (5): 397–404.</mixed-citation><mixed-citation xml:lang="ru">Abadi U., Yarchovsky-Dolberg O., Ellis M.H. Immune thrombocytopenia: recent progress in pathophysiology and treatment. Clin Appl Thromb Hemost 2015;21 (5): 397–404.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Lanzkowsky P., ed. Manual of pediatric hematology and oncology. Elsevier; 2005 Jun. 4th ed; chapter 10, p: 250–9.</mixed-citation><mixed-citation xml:lang="ru">Lanzkowsky P., ed. Manual of pediatric hematology and oncology. Elsevier; 2005 Jun. 4th ed; chapter 10, p: 250–9.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Imbach P., Kühne T., Müller D., Berchtold W., Zimmerman S., Elalfy M., et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer 2006; 46 (3): 351–6.</mixed-citation><mixed-citation xml:lang="ru">Imbach P., Kühne T., Müller D., Berchtold W., Zimmerman S., Elalfy M., et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer 2006; 46 (3): 351–6.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Rodeghiero F., Stasi R., Gernsheimer T., Michel M., Provan D., Arnold D.M., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113 (11): 2386–93.</mixed-citation><mixed-citation xml:lang="ru">Rodeghiero F., Stasi R., Gernsheimer T., Michel M., Provan D., Arnold D.M., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113 (11): 2386–93.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Provan D., Stasi R., Newland A.C., Blanchette V.S., Bolton-Maggs P., Bussel J.B., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115 (2): 168–86.</mixed-citation><mixed-citation xml:lang="ru">Provan D., Stasi R., Newland A.C., Blanchette V.S., Bolton-Maggs P., Bussel J.B., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115 (2): 168–86.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Burness C.B., Keating G.M., Garnock-Jones K.P. Eltrombopag: a review in paediatric chronic immune thrombocytopenia. Drugs 2016; 76 (8): 869–78.</mixed-citation><mixed-citation xml:lang="ru">Burness C.B., Keating G.M., Garnock-Jones K.P. Eltrombopag: a review in paediatric chronic immune thrombocytopenia. Drugs 2016; 76 (8): 869–78.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Liang Y., Zhang L., Gao J., Hu D., Ai Y. Rituximab for children with immune thrombocytopenia: a systematic review. PloS One 2012; 7 (5): e36698.</mixed-citation><mixed-citation xml:lang="ru">Liang Y., Zhang L., Gao J., Hu D., Ai Y. Rituximab for children with immune thrombocytopenia: a systematic review. PloS One 2012; 7 (5): e36698.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Makis A., Gkoutsias A., Palianopoulos T., Pappa E., Papapetrou E., Tsaousi C., et al. Prognostic factors for immune thrombocytopenia outcome in Greek children: A retrospective single-centered analysis. Adv Hematol 2017; 2017: 7878605.</mixed-citation><mixed-citation xml:lang="ru">Makis A., Gkoutsias A., Palianopoulos T., Pappa E., Papapetrou E., Tsaousi C., et al. Prognostic factors for immune thrombocytopenia outcome in Greek children: A retrospective single-centered analysis. Adv Hematol 2017; 2017: 7878605.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Yong M., Schoonen W.M., Li L., Kanas G., Coalson J., Mowat F., et al. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol 2010; 149 (6): 855–64.</mixed-citation><mixed-citation xml:lang="ru">Yong M., Schoonen W.M., Li L., Kanas G., Coalson J., Mowat F., et al. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol 2010; 149 (6): 855–64.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Saeidi S., Jaseb K., Asnafi A.A., Rahim F., Pourmotahari F., Mardaniyan S., et al. Immune thrombocytopenic purpura in children and adults: a comparative retrospective study in IRAN. Int J Hematol Oncology Stem Cell Res 2014; 8 (3): 30.</mixed-citation><mixed-citation xml:lang="ru">Saeidi S., Jaseb K., Asnafi A.A., Rahim F., Pourmotahari F., Mardaniyan S., et al. Immune thrombocytopenic purpura in children and adults: a comparative retrospective study in IRAN. Int J Hematol Oncology Stem Cell Res 2014; 8 (3): 30.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Nazari S.H., Abdollah G.F., Sadeghi K.M. Epidemiology of idiopathic thrombocytopenic purpura in children. Iran J Pediatric Hematol Oncol 2012; 2 (1): 35–9.</mixed-citation><mixed-citation xml:lang="ru">Nazari S.H., Abdollah G.F., Sadeghi K.M. Epidemiology of idiopathic thrombocytopenic purpura in children. Iran J Pediatric Hematol Oncol 2012; 2 (1): 35–9.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. AL-Zuhairy S.H. Evaluation of prognostic factors in newly diagnosed childhood primary immune thrombocytopenia (ITP): two-year prospective study at Al-Sadder Hospital, Missan Province. Med J Babylon 2013; 10: 855–69.</mixed-citation><mixed-citation xml:lang="ru">AL-Zuhairy S.H. Evaluation of prognostic factors in newly diagnosed childhood primary immune thrombocytopenia (ITP): two-year prospective study at Al-Sadder Hospital, Missan Province. Med J Babylon 2013; 10: 855–69.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. France E.K., Glanz J., Xu S., Hambidge S., Yamasaki K., Black S.B., et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 2008; 121 (3): e687–92.</mixed-citation><mixed-citation xml:lang="ru">France E.K., Glanz J., Xu S., Hambidge S., Yamasaki K., Black S.B., et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 2008; 121 (3): e687–92.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Söğüt G., Leblebisatan G., Barutçu A., Kilinç Y., Şaşmaz H.İ. Evaluation of Pediatric Patients with Immune Thrombocytopenia Regarding Clinical Course and Treatment Response: A Retrospective Single-Center Experience. Pediatr Pract Res 2020; 8 (2): 38–42.</mixed-citation><mixed-citation xml:lang="ru">Söğüt G., Leblebisatan G., Barutçu A., Kilinç Y., Şaşmaz H.İ. Evaluation of Pediatric Patients with Immune Thrombocytopenia Regarding Clinical Course and Treatment Response: A Retrospective Single-Center Experience. Pediatr Pract Res 2020; 8 (2): 38–42.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Al-Samkari H., Kuter D.J. Lactate dehydrogenase is elevated in immune thrombocytopenia and inversely correlates with platelet count. Br J Haematol 2019; 187 (3): e61–4.</mixed-citation><mixed-citation xml:lang="ru">Al-Samkari H., Kuter D.J. Lactate dehydrogenase is elevated in immune thrombocytopenia and inversely correlates with platelet count. Br J Haematol 2019; 187 (3): e61–4.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Grimaldi-Bensouda L., Nordon C., Leblanc T., Abenhaim L., Allali S., Armari-Alla C., et al. Childhood immune thrombocytopenia: A nationwide cohort study on condition management and outcomes. Pediatr Blood Cancer 2017; 64 (7): e26389.</mixed-citation><mixed-citation xml:lang="ru">Grimaldi-Bensouda L., Nordon C., Leblanc T., Abenhaim L., Allali S., Armari-Alla C., et al. Childhood immune thrombocytopenia: A nationwide cohort study on condition management and outcomes. Pediatr Blood Cancer 2017; 64 (7): e26389.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Singh G., Bansal D., Wright N.A. Immune thrombocytopenia in children: Consensus and controversies. Ind J Pediatr 2020; 87 (2): 150–7.</mixed-citation><mixed-citation xml:lang="ru">Singh G., Bansal D., Wright N.A. Immune thrombocytopenia in children: Consensus and controversies. Ind J Pediatr 2020; 87 (2): 150–7.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Güngör T., Bilir Ö.A., Çulha V.K., Güngör A., Kara A., Azık F.M., et al. Retrospective evaluation of children with immune thrombocytopenic purpura and factors contributing to chronicity. Pediatr Neonatol 2019; 60 (4): 411–6.</mixed-citation><mixed-citation xml:lang="ru">Güngör T., Bilir Ö.A., Çulha V.K., Güngör A., Kara A., Azık F.M., et al. Retrospective evaluation of children with immune thrombocytopenic purpura and factors contributing to chronicity. Pediatr Neonatol 2019; 60 (4): 411–6.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Donato H., Picón A., Martinez M., Rapetti M.C., Rosso A., Gomez S., et al. Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: a multicentered study from Argentina. Pediatr Blood Cancer 2009; 52 (4): 491–6.</mixed-citation><mixed-citation xml:lang="ru">Donato H., Picón A., Martinez M., Rapetti M.C., Rosso A., Gomez S., et al. Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: a multicentered study from Argentina. Pediatr Blood Cancer 2009; 52 (4): 491–6.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Watts R.G. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama. Clini Pediatr 2004; 43 (8): 691–702.</mixed-citation><mixed-citation xml:lang="ru">Watts R.G. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama. Clini Pediatr 2004; 43 (8): 691–702.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Bansal D., Bhamare T.A., Trehan A., Ahluwalia J., Varma N., Marwaha R.K. Outcome of chronic idiopathic thrombocytopenic purpura in children. Pediatr Blood Cancer 2010; 54 (3): 403–7.</mixed-citation><mixed-citation xml:lang="ru">Bansal D., Bhamare T.A., Trehan A., Ahluwalia J., Varma N., Marwaha R.K. Outcome of chronic idiopathic thrombocytopenic purpura in children. Pediatr Blood Cancer 2010; 54 (3): 403–7.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Akbayram S., Dogan M., Ustyol L., Akgun C., Peker E., Bilici S., et al. The clinical outcome of 260 pediatric ITP patients in one center. Clin Appl Thromb Hemost 2011; 17 (6): е30–5.</mixed-citation><mixed-citation xml:lang="ru">Akbayram S., Dogan M., Ustyol L., Akgun C., Peker E., Bilici S., et al. The clinical outcome of 260 pediatric ITP patients in one center. Clin Appl Thromb Hemost 2011; 17 (6): е30–5.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
